Regeneron Pharmaceuticals and Telix Pharmaceuticals have announced a significant partnership aimed at accelerating the development and commercialization of novel radiopharmaceutical…
Read More
AbbVie Secures Up to $745 Million in Pain Pipeline Deal with Chinese Biopharma Haisco
AbbVie, a global biopharmaceutical giant, has finalized a significant strategic collaboration with Haisco Pharmaceutical Group, a prominent Chinese biopharmaceutical company.…
Read More
Lilly is now the top pharma company by revenue as Mounjaro (+99%) and Zepbound (+175%) combine for $36.5B in FY2025
Eli Lilly and Company has achieved a historic milestone, concluding fiscal year 2025 as the world’s highest-earning pharmaceutical company by…
Read More
Gan & Lee Pharmaceuticals Secures Key South Korean Partnership for Bofanglutide Development and Commercialization
Gan & Lee Pharmaceuticals has announced a significant licensing agreement with JW Pharmaceutical, granting the South Korean biopharmaceutical company exclusive…
Read More
Bristol Myers Squibb and Oxford BioTherapeutics Forge Alliance to Pioneer Novel T-Cell Engager Therapies for Solid Tumors
Bristol Myers Squibb (BMS) and Oxford BioTherapeutics (OBT) have announced a significant strategic alliance aimed at discovering and developing a…
Read More
Pharma 50: Keytruda holds the top brand slot, but tirzepatide and semaglutide have already passed it at the molecule level in FY2025
Merck’s Keytruda (pembrolizumab), a cornerstone of modern oncology, maintained its position as the pharmaceutical industry’s leading brand in Fiscal Year…
Read More
Precision Medicine in Early Oncology Trials: Biomarkers as Strategic Drivers – Pharmaceutical Technology
The landscape of oncology drug development is undergoing a profound transformation, increasingly centered on precision immunotherapies where biomarker-defined patient populations…
Read More
Pharma 50: The 50 best-selling drugs of FY2025
The pharmaceutical industry in Fiscal Year 2025 was defined by a dynamic interplay of enduring blockbuster powerhouses and the dramatic…
Read More
Roche and C4 Therapeutics Forge Strategic Alliance to Pioneer Degrader-Antibody Conjugates for Novel Cancer Therapies
Roche and C4 Therapeutics Forge Strategic Alliance to Pioneer Degrader-Antibody Conjugates for Novel Cancer Therapies Roche, a global pharmaceutical giant,…
Read More
Emerging therapies bring hope for frail HNSCC patients unfit for standard treatment – Pharmaceutical Technology
The global burden of head and neck squamous cell carcinoma (HNSCC) is on an upward trajectory, with an estimated increase…
Read More
